A "new" Valuation Methodology

Facebook and Groupon... what are they worth?

There are a lot of people saying that they are bringing about a new way of valuing companies. I call bullshit.


Groupon had an operating loss of $420 million last year. But it thinks investors in its upcoming initial public offering should look at “adjusted consolidated segment operating income” (adjusted CSOI) instead.

It’s easy to see why Groupon wants prospective shareholders to look at its accounts this way. Strip out marketing expenses, acquisition-related costs, stock compensation, interest expense and payments to the tax man and, presto, the Chicago startup led by Andrew Mason earned $60.6 million. If investors accepted this fantastical form of accounting, all sorts of companies would be worth billions more too.

Groupon argues that adding customers through marketing is a one-time process; stock compensation doesn’t result in direct cash outlays; and taxes and interest payments aren’t relevant because Groupon doesn’t have debt and is still technically “losing money.” In the real world customers leave and need to be replaced by new ones, stock options dilute existing shareholders, and taxes are eventually paid. But suspend disbelief and imagine how this thinking might impact the values of other companies.

Take Netflix. The online video company is growing at warp speed and spending heavily on marketing to attract new customers. Use Groupon’s arithmetic and this cost can be ignored. Netflix also pays taxes and rewards executives with stock. Subtract all of these figures from its 2010 accounts, and it would have had around $600 million of adjusted CSOI. Today, Netflix is valued at around 48 times trailing operating profits of $284 million. Substitute CSOI, and Netflix would be worth $28 billion, twice its market cap.

Or consider an old-school enterprise like Johnson & Johnson. Last year J&J had multiple product recalls. Under adjusted CSOI costs associated with these, like legal bills, advertising, and factory fixes may be treated as one-time expenses. And why stop there? Once a drug is invented, the formula isn’t forgotten, so research and development is a non-recurring cost too.

Do the numbers, and J&J’s CSOI would be about $10 billion higher than its 2010 operating profit line. At the same valuation multiple that J&J now fetches, using CSOI would add $100 billion to J&J’s worth.

This is not a new valuation methodology, it is a pile of crap which has been stuck in a dark corner since 2001, and somehow has got to see the light of day again. Why? I have no idea. Herd idiocy I suppose. Anyway, if you think you can make money off the similarly stupidly priced Facebook, good luck, and you might be able to do it. Just be aware, the company 'aint worth what it says it is.

Comments

Popular posts from this blog

Top 10 Ways to Not Suck at Driving

This is just disgusting....